[Results from the LIFE study: promising effects of new hypertensive agents].
Nilsson
Peter
P
Avdelningen för medicin, Universitetssjukhuset MAS, Malmö. Peter.Nilsson@medforsk.mas.lu.se
Kahan
Thomas
T
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D017379:Hypertrophy, Left Ventricular / Q000150:complications / Q000188:drug therapy*; D019808:Losartan / Q000627:therapeutic use*; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D000804:Angiotensin II; D001262:Atenolol; D019808:Losartan
Resultat från LIFE-studien: Lovande effekter av en ny klass hypertoniläkemedel.